Cited by 315Cancer survivorship and careTryptophan and brain disordersCancer-related cognitive impairment studies

Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer

Open access
Bower, Julienne E., Ganz, Patricia A., Tao, May Lin, Hu, Wenhua, Belin, Thomas R., Sepah, Saviz, Cole, Steve, Aziz, Najib·2009·Clinical Cancer Research

Abstract

Purpose: Biomarkers of radiation-induced behavioral symptoms, such as fatigue, have not been identified. Studies linking inflammatory processes to fatigue in cancer survivors led us to test the hypothesis that activation of the proinflammatory cytokine network is associated with fatigue symptoms during radiation therapy for breast and prostate cancer. Experimental Design: Individuals with early-stage breast (n = 28) and prostate cancer (n= 20) completed questionnaires and provided blood samples for determination of serum levels of interleukin 1β (IL-1β) and IL-6 at assessments conducted before, during, and after a course of radiation therapy. Serum markers of proinflammatory cytokine activity, including IL-1 receptor antagonist and C-reactive protein, were examined in a subset of participants. Random coefficient models were used to evaluate the association between changes in cytokine levels and fatigue. Results: As expected, there was a significant increase in fatigue during radiation treatment. Changes in serum levels of inflammatory markers C-reactive protein and IL-1 receptor antagonist were positively associated with increases in fatigue symptoms (Ps < 0.05), although serum levels of IL-1β and IL-6 were not associated with fatigue. These effects remained significant (Ps < 0.05) in analyses controlling for potential biobehavioral confounding factors, including age, body mass index, hormone therapy, depression, and sleep disturbance. Conclusions: Results suggest that activation of the proinflammatory cytokine network and associated increases in downstream biomarkers of proinflammatory cytokine activity are associated with fatigue during radiation therapy for breast and prostate cancer.(Clin Cancer Res 2009;15(17):5534–40)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-2584

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., Cole, S., & Aziz, N.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Bower, Julienne E.
Venue
Clinical Cancer Research
Published
2009-08-31
Volume
15
Issue
17
Pages
5534-5540
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2068185418
Cited by
315
References
44
Citations by year
2026: 10 · 2025: 13 · 2024: 9 · 2023: 21 · 2022: 23 · 2021: 18 · 2020: 26 · 2019: 20 · 2018: 16 · 2017: 18 · 2016: 16 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 35
FWCI
10.84
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Health and Human Services
  • California Breast Cancer Research Program
  • National Institutes of Health
  • National Cancer Institute (K07CA090407, K07-CA90407, R01CA116778)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
radiation-induced fatigue, inflammatory markers, inflammatory cytokines, breast cancer, prostate cancer, IL-1β, interleukin-6, C-reactive protein, interleukin-1 receptor antagonist, radiotherapy complications, cancer survivors
MeSH terms
Adult, Aged, Breast Neoplasms, C-Reactive Protein, Fatigue, Female, Humans, Inflammation, Male, Middle Aged, Prostatic Neoplasms, Biomarkers, Interleukin-6, Interleukin-1beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review